GLP-1 Peptide Atlas, by Delfa

← Trials/Trial dossier/NCT04303819

Completed

The Effect of Exenatide on Fasting Bile Acids

The Effect of Exenatide on Fasting Bile Acids in Newly Diagnosed Type 2 Diabetes Mellitus Patients, a Pilot Study

Lead sponsor

Beijing Chao Yang Hospital

Asset

Exenatide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Type 2 diabetes

Key I/E criterion

—

Primary endpoint

•Plasma total bile acids in fasting state

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT04303819

Org study ID20131212

Timeline

Milestones

Study start2020-01-05actual

Primary completion2020-01-28actual

Study completion2020-01-31actual

Study first posted2020-03-11actual

Last update posted2020-06-11actual

Assets

Investigational agents

Exenatide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years

Maximum age65 Years

SexAll

Healthy volunteersNot accepted

Sampling methodNon probability sample

Study population text

Chinese population

Inclusion criteria

•Newly diagnosed T2DM patients

Exclusion criteria

•History of hepatobiliary or pancreatic diseases

•History of anti-diabetic drugs intake

•Change of anti-dyslipidemia therapy regimen

•Estimated glomerular filtration rate less than 60 mL/min/1.73 m^2

•Pregnancy

Endpoints (6)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes

Weight & body composition

Other (unclassified)

Weight & body composition

1 endpoint

Secondary/protocol endpoint

Body mess index

Time frame:12 weeks

BMI, change

change from baseline, improvement

Glycemic / diabetes

4 endpoints

Secondary/protocol endpoint

fasting plasma glucose

Time frame:12 weeks

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Secondary/protocol endpoint

Glycated hemoglobin A1c

Time frame:12 weeks

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

C-peptide

Time frame:12 weeks

concentration, improvement

Secondary/protocol endpoint

Fasting serum insulin

Time frame:12 weeks

descriptive

Other (unclassified)

1 endpoint

Primary/protocol endpoint/low confidence

Plasma total bile acids in fasting state

Time frame:12 weeks

concentration, descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

The effect of exenatide on fasting bile acids in newly diagnosed type 2 diabetes mellitus patients, a pilot study.
BMC pharmacology & toxicology2020 Jun 15PMID32539783doi:10.1186/s40360-020-00422-5via clinicaltrials gov reference derived + pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.